Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 21, 2004

Primary Completion Date

April 1, 2010

Study Completion Date

April 1, 2010

Conditions
Neurofibromatosis 1Neurofibroma, Plexiform
Interventions
DRUG

Pirfenidone

Pirfenidone orally as capsules three times a day approximately every 8 hours for cycles of 28 days with no rest period between cycles (28 day treatment cycles); 500 mg/m\^2 every 8 hours (1500 mg/m2/day).

Trial Locations (15)

10003

Beth Israel Medical Center, New York

13210

SUNY Upstate Medical University, Syracuse

15213

Childrens Hospital, Pittsburgh, Pittsburgh

19104

Childrens Hospital, Philadelphia, Philadelphia

20010

Childrens National Medical Center, Washington D.C.

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

21287

Johns Hopkins Oncology Center, Baltimore

35233

University of Alabama, Birmingham

44195

Cleveland Clinic, Cleveland

55905

Mayo Clinic, Rochester, Rochester

60614

Childrens Memorial Hospital, Chicago, Chicago

63110

St. Louis Children's Hospital, St Louis

77030

Texas Children's Hospital, Houston

02115

Childrens Hospital, Dana-Farber Cancer Institute, Boston

97201-3098

Oregon Health Sciences University, Portland

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00076102 - Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas | Biotech Hunter | Biotech Hunter